BioCryst Pharmaceuticals, Inc. (BCRX)
Automate Your Wheel Strategy on BCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including BCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCRX
- Rev/Share 2.4104
- Book/Share -2.1636
- PB -4.6682
- Debt/Equity -1.7591
- CurrentRatio 2.9247
- ROIC 0.1005
- MktCap 2113425000.0
- FreeCF/Share -0.1306
- PFCF -77.4517
- PE -39.4559
- Debt/Assets 1.6561
- DivYield 0
- ROE 0.1143
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BCRX | Cantor Fitzgerald | -- | Overweight | -- | $20 | April 29, 2025 |
| Initiation | BCRX | Wedbush | -- | Outperform | -- | $15 | Feb. 25, 2025 |
News
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.
Read More
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for June 4th
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BCRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2025.
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.
Read More
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations.
Read More
Best Momentum Stocks to Buy for May 9th
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
Read More
New Strong Buy Stocks for May 9th
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Read More
Why BioCryst (BCRX) Might be Well Poised for a Surge
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
BioCryst: Strong Opportunity For A Double With A Proven Therapy
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Positive
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy reliance on ORLADEYO, BCRX stock remains a "Buy" due to its strong market presence and growth potential in the hereditary angioedema therapy market. The 10-K report highlights competition, including late-stage therapies and an upcoming PDUFA date for KalVista's sebetralstat, which could impact market dynamics.
Read More
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Steven Seedhouse - Cantor Maury Raycroft - Jefferies Jessica Fye - JP Morgan Stacy Ku - TD Cowen Gena Wang - Barclays Laura Chico - Wedbush Securities Liisa Bayko - Evercore ISI Serge Belanger - Needham & Co. Jonathan Wolleben - Citizens JMP Operator Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. …
Read More
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
Read More
BioCryst Appoints Steve Frank to Board of Directors
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors.
Read More
BioCryst to Present at Upcoming Investor Conferences
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Read More
BioCryst to Report First Quarter 2025 Financial Results on May 5
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025.
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats.
Read More
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—
Read More
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function –
Read More
BioCryst to Present at Upcoming Investor Conferences
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Read More
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
Read More
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.
Read More
About BioCryst Pharmaceuticals, Inc. (BCRX)
- IPO Date 1994-03-04
- Website https://www.biocryst.com
- Industry Biotechnology
- CEO Mr. Jon P. Stonehouse
- Employees 580